165 related articles for article (PubMed ID: 25230579)
1. Antibody therapy to human L1CAM in a transgenic mouse model blocks local tumor growth but induces EMT.
Doberstein K; Harter PN; Haberkorn U; Bretz NP; Arnold B; Carretero R; Moldenhauer G; Mittelbronn M; Altevogt P
Int J Cancer; 2015 Mar; 136(5):E326-39. PubMed ID: 25230579
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic antibodies to human L1CAM: functional characterization and application in a mouse model for ovarian carcinoma.
Wolterink S; Moldenhauer G; Fogel M; Kiefel H; Pfeifer M; Lüttgau S; Gouveia R; Costa J; Endell J; Moebius U; Altevogt P
Cancer Res; 2010 Mar; 70(6):2504-15. PubMed ID: 20215505
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of L1CAM is associated with tumor progression and prognosis via ERK signaling in gastric cancer.
Ito T; Yamada S; Tanaka C; Ito S; Murai T; Kobayashi D; Fujii T; Nakayama G; Sugimoto H; Koike M; Nomoto S; Fujiwara M; Kodera Y
Ann Surg Oncol; 2014 Feb; 21(2):560-8. PubMed ID: 24046108
[TBL] [Abstract][Full Text] [Related]
4. Targeting l1 cell adhesion molecule using lentivirus-mediated short hairpin RNA interference reverses aggressiveness of oral squamous cell carcinoma.
Hung SC; Wu IH; Hsue SS; Liao CH; Wang HC; Chuang PH; Sung SY; Hsieh CL
Mol Pharm; 2010 Dec; 7(6):2312-23. PubMed ID: 21033655
[TBL] [Abstract][Full Text] [Related]
5. L1 cell adhesion molecule induces melanoma cell motility by activation of mitogen-activated protein kinase pathways.
Yi YS; Baek KS; Cho JY
Pharmazie; 2014 Jun; 69(6):461-7. PubMed ID: 24974583
[TBL] [Abstract][Full Text] [Related]
6. L1 cell adhesion molecule promotes tumorigenicity and metastatic potential in non-small cell lung cancer.
Hai J; Zhu CQ; Bandarchi B; Wang YH; Navab R; Shepherd FA; Jurisica I; Tsao MS
Clin Cancer Res; 2012 Apr; 18(7):1914-24. PubMed ID: 22307136
[TBL] [Abstract][Full Text] [Related]
7. Generation, characterization and preclinical studies of a human anti-L1CAM monoclonal antibody that cross-reacts with rodent L1CAM.
Cho S; Park I; Kim H; Jeong MS; Lim M; Lee ES; Kim JH; Kim S; Hong HJ
MAbs; 2016; 8(2):414-25. PubMed ID: 26785809
[TBL] [Abstract][Full Text] [Related]
8. Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma.
Schäfer H; Dieckmann C; Korniienko O; Moldenhauer G; Kiefel H; Salnikov A; Krüger A; Altevogt P; Sebens S
Cancer Lett; 2012 Jun; 319(1):66-82. PubMed ID: 22210381
[TBL] [Abstract][Full Text] [Related]
9. Myofibroblast-induced tumorigenicity of pancreatic ductal epithelial cells is L1CAM dependent.
Schäfer H; Geismann C; Heneweer C; Egberts JH; Korniienko O; Kiefel H; Moldenhauer G; Bachem MG; Kalthoff H; Altevogt P; Sebens S
Carcinogenesis; 2012 Jan; 33(1):84-93. PubMed ID: 22095073
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers.
Suzuki M; Kato-Nakano M; Kawamoto S; Furuya A; Abe Y; Misaka H; Kimoto N; Nakamura K; Ohta S; Ando H
Cancer Sci; 2009 Sep; 100(9):1623-30. PubMed ID: 19555390
[TBL] [Abstract][Full Text] [Related]
11. EMT-associated up-regulation of L1CAM provides insights into L1CAM-mediated integrin signalling and NF-κB activation.
Kiefel H; Bondong S; Pfeifer M; Schirmer U; Erbe-Hoffmann N; Schäfer H; Sebens S; Altevogt P
Carcinogenesis; 2012 Oct; 33(10):1919-29. PubMed ID: 22764136
[TBL] [Abstract][Full Text] [Related]
12. alpha5-integrin is crucial for L1CAM-mediated chemoresistance in pancreatic adenocarcinoma.
Sebens Müerköster S; Kötteritzsch J; Geismann C; Gast D; Kruse ML; Altevogt P; Fölsch UR; Schäfer H
Int J Oncol; 2009 Jan; 34(1):243-53. PubMed ID: 19082495
[TBL] [Abstract][Full Text] [Related]
13. Aberrant l1 cell adhesion molecule affects tumor behavior and chemosensitivity in anaplastic thyroid carcinoma.
Kim KS; Min JK; Liang ZL; Lee K; Lee JU; Bae KH; Lee MH; Lee SE; Ryu MJ; Kim SJ; Kim YK; Choi MJ; Jo YS; Kim JM; Shong M
Clin Cancer Res; 2012 Jun; 18(11):3071-8. PubMed ID: 22472175
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells.
Clary BM; Coveney EC; Philip R; Blazer DG; Morse M; Gilboa E; Lyerly HK
Cancer Gene Ther; 1997; 4(2):97-104. PubMed ID: 9080118
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of L1CAM significantly reduces metastasis in a xenograft model of human melanoma: L1CAM is a potential target for anti-melanoma therapy.
Ernst AK; Putscher A; Samatov TR; Suling A; Galatenko VV; Shkurnikov MY; Knyazev EN; Tonevitsky AG; Haalck T; Lange T; Maar H; Schröder-Schwarz J; Riecken K; Schumacher U; Wicklein D
PLoS One; 2018; 13(2):e0192525. PubMed ID: 29432466
[TBL] [Abstract][Full Text] [Related]
16. Development of a Theranostic Convergence Bioradiopharmaceutical for Immuno-PET Based Radioimmunotherapy of L1CAM in Cholangiocarcinoma Model.
Song IH; Jeong MS; Hong HJ; Shin JI; Park YS; Woo SK; Moon BS; Kim KI; Lee YJ; Kang JH; Lee TS
Clin Cancer Res; 2019 Oct; 25(20):6148-6159. PubMed ID: 31337646
[TBL] [Abstract][Full Text] [Related]
17. Epithelial mucin-1 (MUC1) expression and MA5 anti-MUC1 monoclonal antibody targeting in multiple myeloma.
Burton J; Mishina D; Cardillo T; Lew K; Rubin A; Goldenberg DM; Gold DV
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3065s-3072s. PubMed ID: 10541345
[TBL] [Abstract][Full Text] [Related]
18. L1CAM-integrin interaction induces constitutive NF-kappaB activation in pancreatic adenocarcinoma cells by enhancing IL-1beta expression.
Kiefel H; Bondong S; Erbe-Hoffmann N; Hazin J; Riedle S; Wolf J; Pfeifer M; Arlt A; Schäfer H; Müerköster SS; Altevogt P
Oncogene; 2010 Aug; 29(34):4766-78. PubMed ID: 20543863
[TBL] [Abstract][Full Text] [Related]
19. Slug-dependent upregulation of L1CAM is responsible for the increased invasion potential of pancreatic cancer cells following long-term 5-FU treatment.
Lund K; Dembinski JL; Solberg N; Urbanucci A; Mills IG; Krauss S
PLoS One; 2015; 10(4):e0123684. PubMed ID: 25860483
[TBL] [Abstract][Full Text] [Related]
20. Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis.
Knogler K; Grünberg J; Zimmermann K; Cohrs S; Honer M; Ametamey S; Altevogt P; Fogel M; Schubiger PA; Novak-Hofer I
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):603-11. PubMed ID: 17255283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
